[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroprotective\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroprotective":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100596633","interventions-for-silent-brain-infarction-and-perioperative-neurocognitive-disorders-in-cardiovascular-surgery-100596633",false,"NCT07048002","Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery","Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)","INSPIRE","Inclusion criteria:\n\n* Male or female adult patients aged 60 years or older\n* Receiving elective cardiovascular surgery with cardiopulmonary bypass\n* Written Informed consent provided\n\nExclusion criteria:\n\n* Contraindication to MRI scanning\n* Not suitable for receiving interventions to achieve NeuroFirst target bundle\n* Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments\n* Breastfeeding or pregnancy\n* Terminal illness with a life expectancy of less than 3 months\n* Mental or legal disability\n* current enrollment in other interventional study","ALL","60 Years",{"count":20,"type":21},912,"ESTIMATED","INTERVENTIONAL",[24],"NA","the purpose of the study is to investigate whether a combined anesthetic targets bundle, known as the NeuroFirst strategy, focused on neurological protection, can reduce the incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) in patients undergoing cardiac surgery. Additionally, the trial will assess the safety of this strategy.\n\nThe NeuroFirst target bundle incorporates multiple parameters, including mean arterial pressure (MAP), bispectral index (BIS), regional cerebral oxygen saturation (rSO2), and arterial inflow temperature during cardiopulmonary bypass.\n\nThe primary question this study seeks to answer is: Does the NeuroFirst strategy reduce the incidence of SBI and PND in cardiac surgery?\n\nTo address this, researchers will compare the NeuroFirst strategy with routine institutional practices based on published guidelines. Participants will be randomly assigned to either the NeuroFirst group or the routine care group. All participants will undergo magnetic resonance imaging (MRI), be assessed using the Confusion Assessment Method (CAM) and the Montreal Cognitive Assessment (MoCA), and be followed for up to one year postoperatively.",[27,28,29,30],"Silent Brain Infarction","Neurocognitive Disorders","Cardiac Surgery","Neuroprotective","RECRUITING","2025-11-19",{"date":34,"type":35},"2025-11-24","ACTUAL",{"date":37,"type":35},"2025-07-06",{"date":39,"type":21},"2028-10-31",{"name":41,"class":42},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100558365","neuroprotective-effect-of-nano-pso-in-patients-who-used-to-consume-psychoactive-substances-100558365","NCT06550167","Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances","Neuroprotective Effect of Omega (Nano PSO), Changes in Neurotrophic BDNF and VEGF, and Their Association With Cognitive Status in Patients Who Used to Consume Psychoactive Substances","Inclusion Criteria:\n\n* Patients who are multiple users of methamphetamines, cocaine, and cannabis with or without alcohol and tobacco, and have a history of at least 3 years of consumption.\n* Patients who accept informed consent to participate in the protocol.\n* Male gender.\n* Age between 18-50 years in the withdrawal phase currently in residential treatment\n\nExclusion Criteria:\n\n* Individuals under 18 years of age.\n* Patients who do not sign the informed consent.\n* Discharge of patients prior to the stipulated 6 months, requested by family members.\n* Patients with developed or known allergies.\n* Patients who are consuming NSAIDs, MAOIs (monoamine oxidase Inhibitor), active chronic inflammatory diseases, or any type of cancer","MALE","18 Years","50 Years",{"count":55,"type":21},80,[24],"Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption present important degeneration processes mediated by Neuroinflammation, oxidative stress and excitotoxicity. At the moment there is no effective treatment that can reduce the damage. The effectiveness of Omega 5 has been demonstrated in different disorders of the nervous system; However, very little has been elucidated about the mechanisms of regulation and activation in consumer patients. Omega 5 Nano-PSO has an important role in mechanisms of cell survival in different pathological events.\n\nIn this project aims to explain the possible mechanisms underlying the morphological changes and pathologies associated with oxidative stress and inflammation, since it could be a useful strategy to counteract the effects of substances of abuse on brain cells.\n\nOmega 5 (Nano PSO) will modify the levels of neurotrophic factors through the decrease in inflammation and reactive oxygen species in patient-consumers of substances, reducing neuronal death and therefore cognitive deterioration. Methodological design Type of study: Clinical trial, randomized controlled, double blind. Research Headquarters: This work will be carried out at the University Center for Health Science with the participation of the \"My family is waiting for me\" rehabilitation centers. Study Period: 2 years",[59,30],"Addiction;Drug(S);LSD",[61,30,62],"Addiction, Drug","pomegranate seed oil","2024-08-09",{"date":65,"type":35},"2024-08-12",{"date":67,"type":35},"2024-03-15",{"date":69,"type":21},"2027-03-15",{"name":71,"class":72},"Distribuidora Biolife SA de CV","INDUSTRY",1]